Australia Psychedelics

New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin Therapy A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an...

Welcome to the inaugural episode of the Benzinga Psychedelics Podcast. In this exciting kickoff, we're joined by Joel Latham, experienced biotech industry leader and CEO of Incannex Healthcare (NASDAQ:IXHL). Dive into our engaging conversation as we explore Incannex's strategic expansion into...

The new treatments, given to two people under the guidance of Dr. Eli Kotler and Dr. Ted Cassidy, are framed within Australia's Therapeutic Goods Administration (TGA) program authorizing psychiatrists to provide these medicines for specific mental health conditions. Kotler and Cassidy, early...

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase 1 For IV Psilocin First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused...

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members. The...

Melbourne will soon open Clarion Clinics’ first exclusively dedicated facility to provide psychedelic-assisted therapies legalized in Australia.  The subsidiary to biotech Incannex Healthcare (NASDAQ: IXHL) received the required Human Research Ethics Committee (HREC) endorsement for...

Canadian psychedelics biotech Tryp Therapeutics Inc. has entered into an agreement with Australian publicly-trading drug vehicle developer Exopharm Ltd. for the acquisition of 100% of Tryp’s issued and outstanding common shares.  The arm’s length transaction, dated Dec. 8...

The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (APS) is all set. The Canadian MDXX class molecules company, together with...

As Australia’s psychedelic program launches, PharmAla Biotech Holdings Inc.’s (OTC: PMBHF) new Aussie joint business Cortexa has executed its first purchase order for PharmAla’s GMP-compliant MDMA in both finished capsule and raw API forms. The MDXX-class molecules developer will...

Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. Hysek AG toward an exclusive partnership for the import and distribution of licensed MDMA and psilocybin products into Australia, of which...

On May 1, new partners Canadian psychedelics developer PharmAla Biotech and Australian digital healthcare business Vitura Health (formerly Cronos Australia) announced the definitive establishment of a 50-50 joint venture Cortexa.  On May 20, the CEOs of both PharmAla and Vitura hosted a...

While psychedelics reform is clearly gaining momentum, not only in the U.S. but notably in places like Australia and less so Canada. The fact is, all compounds remain currently Schedule I drugs (or equivalents) and thus federally illegal in many countries including the U.S. The...

Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd. Psychennex will take advantage of Australia’s new psychedelics regulations through clinical research programs and...

Australia has announced that it will become the first country in the world to reschedule the medical use of MDMA and Psilocybin, two key ingredients in psychedelic drugs. On Feb. 3, the Therapeutic Goods Administration (TGA) revealed that these substances would be moved from Schedule 9, which...

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech...